Jubilant Ingrevia Ltd.Revenue +24%, EBITDA +51%, Zettaone stake

Jubilant Ingrevia's Q2 FY27 call, held on 27 October 2026, reported record revenue of ₹1,394 crore, up 24%, EBITDA of ₹221 crore, up 51% and the highest in three years, and profit after tax of ₹111 crore, up 60%.

Specialty chemicals earned ₹140 crore of EBITDA at a 25% margin, nutrition revenue rose 50% to ₹270 crore, and chemical intermediates EBITDA rose 26% to ₹64 crore. The company agreed to buy 40% of electronics design firm Zettaone for ₹189 crore, expects it to grow 60% to 70% this year, and says competitor plant closures in Europe could lift acetic anhydride demand from early next calendar year. Management kept its ₹750 crore to ₹800 crore annual guidance, hoping to be near the upper end, and said it will give visibility on the large CDMO contract within a few weeks.

Capex will be at least ₹400 crore to ₹500 crore a year, and a new multipurpose plant is due by year-end. Vitamin B3 prices have softened and agro-chemical pricing is muted by Chinese capacity.